China Authorizes CoronaVac COVID-19 Vaccine

Beijing-based Sinovac Biotech Ltd. announced that the China National Medical Products Administration has granted conditional marketing authorization to Sinovac for CoronaVac, Sinovac’s COVID-19 vaccine.

The company stated in a press release issued on February 8, 2021, the approval is based on the results of the two-month data of phase III clinical trials. The final results are not yet available, and the efficacy and safety results shall be further confirmed.

Mr. Yin Weidong, Chairman, President, and CEO of Sinovac, commented, "The COVID-19 pandemic continues around the world, and the fight is far from over. We look forward to providing safe and effective vaccines to as many individuals as possible to combat this epidemic by increasing the vaccination rate. It is our sincere hope that people’s lives and social and economic activities can return to normal as soon as possible and that we can wear a smile without masks."

CoronaVac is being used under emergency use approval in Indonesia, Brazil, Turkey, and Chile.